- Genetically engineered “ARMORED” tumor infiltrating lymphocytes (TILs) derived (by biopsy or surgical excision) from an individual patient’s tumor specimens
- Selection for tumor-specific TILs
- A “personalized” cellular immunotherapy approach
- No need for co-administration of exogenous IL2, which minimizes side effects
- Currently being tested in animal models. A Phase 1 clinical trial in patients with metastatic solid tumors is currently being planned.